Affiliation: University of Manchester
- Epirubicin for breast cancer may cause considerable venous sclerosisPaula Bolton-Maggs
Department of Clinical Haematology, Manchester Royal Infirmary, Manchester M13 9WL
BMJ 331:816. 2005
- A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDOPaula H B Bolton-Maggs
Department of Haematology, Manchester Royal Infirmary, Manchester, UK
Br J Haematol 135:603-33. 2006....
- Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safetyPaula H B Bolton-Maggs
SHOT Office, Manchester Blood Centre and University of Manchester, Manchester, UK
Br J Haematol 163:303-14. 2013..The recommendations on reduction of errors through a 'back to basics' approach from the first annual SHOT report remain absolutely relevant today...
- Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance schemeP H B Bolton-Maggs
University of Manchester, and Serious Hazards of Transfusion Office, Manchester Blood Centre, Manchester, UK
BJOG 120:873-8. 2013..To highlight the errors associated with the use of anti-D immunoglobulin in RhD antigen-negative women, and their resultant clinical impact during and after pregnancy, and to suggest strategies to reduce these errors...
- Commentary on session: Immune thrombocytopenia nomenclature, guidelines, and natural historyPaula H B Bolton-Maggs
Serious Hazards of Transfusion Programme, University of Manchester, Manchester Blood Centre, Manchester, UK
Semin Hematol 50:S10-1. 2013..Participants noted the two new guidelines gave discrepant advice with regard to splenectomy. Management of ITP is not necessarily straightforward and needs to be tailored to the individual...
- The rare inherited coagulation disordersPaula H B Bolton-Maggs
University of Manchester, Manchester Blood Centre, Plymouth Grove, Manchester, UK
Pediatr Blood Cancer 60:S37-40. 2013..Factor VII and factor XI deficiencies show a poor relationship between the factor level and bleeding risk. Unlike hemophilia, women are equally affected by these RICD and can have problems related to menstruation and childbirth...
- Difficulties and pitfalls in the laboratory diagnosis of bleeding disordersP H B Bolton-Maggs
University of Manchester and Manchester Blood Centre, Manchester, UK
Haemophilia 18:66-72. 2012..Factor XIII deficiency is a rare, but important bleeding disorder, which may be missed or diagnosed late. A discussion and update on this diagnosis is considered in the final section of our review...
- Guidelines for the diagnosis and management of hereditary spherocytosis--2011 updatePaula H B Bolton-Maggs
University of Manchester, Manchester, UK
Br J Haematol 156:37-49. 2012..The diagnostic value of the eosin-5-maleimide (EMA) binding test has been validated in a number of studies with understanding of its limitations...
- Acute immune thrombocytopenic purpura. To treat or not to treat?P Bolton-Maggs
Department of Clinical Haematology, Central Manchester and Manchester Children s University Hospitals, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, England
Hamostaseologie 29:74-5. 2009..It is notable that adults with ITP may die from infection, probably related to therapy...
- von Willebrand disease update: diagnostic and treatment dilemmasP H B Bolton-Maggs
Manchester Royal Infirmary, Oxford Road, Manchester, UK
Haemophilia 14:56-61. 2008..Type 3 VWD is the most severe form of VWD and a new international study is underway to examine the use of prophylaxis...
- Transition of care from paediatric to adult services in haematologyPaula H B Bolton-Maggs
Department of Clinical Haematology, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
Arch Dis Child 92:797-801. 2007..Despite these initiatives only slow progress has been made (usually by enthusiasts) and much work is needed to develop good programmes in many specialties, including non-malignant haematology...
- Optimal haemophilia care versus the realityPaula H B Bolton-Maggs
Manchester Haemophilia Comprehensive Care Centre, Manchester Royal Infirmary, Manchester, UK
Br J Haematol 132:671-82. 2006..The development of inhibitory antibodies seriously complicates the management both in morbidity and cost. While gene therapy has not yet produced the hoped-for cure, new technologies will produce improved products...
- A framework for genetic service provision for haemophilia and other inherited bleeding disordersC A Ludlam
Department of Haematology, Royal Infirmary, Edinburgh, UK
Haemophilia 11:145-63. 2005....
- Haemophilias A and BPaula H B Bolton-Maggs
Department of Haematology, Royal Liverpool Children s Hospital, Liverpool, UK
Lancet 361:1801-9. 2003..The future holds the realistic possibility of gene therapy. However, we must not forget that haemophilia is a worldwide disorder that requires significant economic resources not available for the majority...
- Haemophilia--paucity of evidence, ways forward?Paula H B Bolton-Maggs
Manchester Haemophilia Comprehensive Care Centre, Department of Clinical Haematology, Manchester Royal Infirmary, Manchester, UK
Blood Coagul Fibrinolysis 14:S7-9. 2003..Some preliminary questions can establish areas where new clinical studies are needed...